US NIH Initiates Trial to Assess Mix-Match of COVID-19 Vaccine Booster Shots: CNBC
The National Institutes of Health (NIH) has started an early-stage clinical trial to assess what happens when a…
Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102
Protalix BioTherapeutics Inc (NYSE:PLX) and Chiesi Farmaceutici S.p.A. have provided an update on the clinical development of pegunigalsidase alfa (PRX–102) for the…
Lilly’s Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
Eli Lilly And Co (NYSE:LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib)…
Almost Half of Crohn’s Disease Patients Achieved Endoscopic Response After One Year of Maintenance Treatment with AbbVie’s Risankizumab
AbbVie Inc (NYSE: ABBV) has announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing Skyrizi (risankizumab) achieved the co-primary endpoints of endoscopic response and clinical remission at one year in Crohn's disease.
Bristol Myers’ Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural Mesothelioma
The regulatory authorities in Europe and Canada have approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment…
Lexaria’s DehydraTECHTM Drug Delivery Technology Is Investigating Applications in Multiple Markets Valued Over USD $100 Billion
Developing a safe and effective drug is important, but it’s only part of the picture.
Mereo’s Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome
Mereo BioPharma Group plc (NASDAQ:MREO) has announced data from an interim analysis of an investigator-initiated study of alvelestat, in patients with…
Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials
The FDA has signed off Seres Therapeutics Inc’s (NASDAQ:MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial.…
BeyondSpring’s Plinabulin US Application for Chemo-Induced Neutropenia Under Review
The FDA has accepted for review BeyondSpring Inc’s (NASDAQ:BYSI) marketing application seeking approval for the use of plinabulin in combination with…
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Akebia Therapeutics Inc (NASDAQ:AKBA) and its collaborator Otsuka Holdings (OTC:OTSKY) have announced that the FDA has accepted to review vadadustat’s marketing application for…